Tag: =OPD

Recurrence-Free Survival Longer With Nivolumab Than Ipilimumab in Melanoma

Median duration of recurrence-free survival was 61.1 months with nivolumab and ...

READ MORE

Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance

Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ ...

READ MORE